

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
  
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:11:31 ON 14 NOV 2003

=> file medline, biosis, dgene, wpids

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 17:11:48 ON 14 NOV 2003

FILE 'BIOSIS' ENTERED AT 17:11:48 ON 14 NOV 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'DGENE' ENTERED AT 17:11:48 ON 14 NOV 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 17:11:48 ON 14 NOV 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s annexin

L1 9739 ANNEXIN

=> s MDR or multidrug resistance

L2 27718 MDR OR MULTIDRUG RESISTANCE

=> s l2 and l1

L3 59 L2 AND L1

=> s annexin I

L4 975 ANNEXIN I

=> s l4 and l3

L5 5 L4 AND L3

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 5 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related  
to **annexin** proteins

AN AAY08412 Protein DGENE

AB This invention describes a novel human **annexin** family member,  
P-40 (also known as **annexin I**) which is a member of  
the **MDR (multidrug resistance)** gene family,  
for assessing or modulating **MDR** in a cell. Antisense P-40  
sequences are used to prevent **MDR** in animals, particularly in  
conjunction with cancer treatment. Detecting levels of the P-40 nucleic  
acid, or related RNA, is used to detect cancer (or pathogens) with  
**MDR**, or susceptibility. P-40 nucleic acid can also be used as a  
target for identifying therapeutic agents, e.g. antifungal agents, and  
increasing the nucleic acid expression in plants may be used to develop  
specific resistance. The products of the invention have antitumour and  
antifungal activity.

ACCESSION NUMBER: AAY08412 Protein DGENE

TITLE: Modulating or assessing **multidrug**  
**resistance** related to **annexin** proteins

INVENTOR: Georges E; Wang Y

PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.

PATENT INFO: WO 9921980 A1 19990506 63p

APPLICATION INFO: WO 1998-CA992 19981026

PRIORITY INFO: CA 1997-2219299 19971024

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1999-337419 [28]

CROSS REFERENCES: N-PSDB: AAX57357; AAX57358

DESCRIPTION: Human p-40/**annexin I** protein.

L5 ANSWER 2 OF 5 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related  
to **annexin** proteins

AN AAX57358 DNA DGENE

AB This invention describes a novel human **annexin** family member,  
P-40 (also known as **annexin I**) which is a member of  
the **MDR (multidrug resistance)** gene family,  
for assessing or modulating **MDR** in a cell. Antisense P-40

sequences are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of the P-40 nucleic acid, or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. P-40 nucleic acid can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing the nucleic acid expression in plants may be used to develop specific resistance. The products of the invention have antitumour and antifungal activity.

ACCESSION NUMBER: AAX57358 DNA DGENE  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins  
INVENTOR: Georges E; Wang Y  
PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.  
PATENT INFO: WO 9921980 A1 19990506 63p  
APPLICATION INFO: WO 1998-CA992 19981026  
PRIORITY INFO: CA 1997-2219299 19971024  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-337419 [28]  
CROSS REFERENCES: P-PSDB: AAY08413  
DESCRIPTION: Human p-40/**annexin I** antisense DNA.

L5 ANSWER 3 OF 5 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related to **annexin** proteins

AN AAX57357 DNA DGENE

AB This invention describes a novel human **annexin** family member, P-40 (also known as **annexin I**) which is a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR** in a cell. Antisense P-40 sequences are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of the P-40 nucleic acid, or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. P-40 nucleic acid can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing the nucleic acid expression in plants may be used to develop specific resistance. The products of the invention have antitumour and antifungal activity.

ACCESSION NUMBER: AAX57357 DNA DGENE  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins  
INVENTOR: Georges E; Wang Y  
PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.  
PATENT INFO: WO 9921980 A1 19990506 63p  
APPLICATION INFO: WO 1998-CA992 19981026  
PRIORITY INFO: CA 1997-2219299 19971024  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-337419 [28]  
CROSS REFERENCES: P-PSDB: AAY08412  
DESCRIPTION: Human p-40/**annexin I** DNA.

L5 ANSWER 4 OF 5 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

TI Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .

AN 2003-328406 [31] WPIDS

AB US2002168765 A UPAB: 20030516

NOVELTY - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC), is new. The cells within (I) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and **annexin II** (lipocortin 2).

DETAILED DESCRIPTION - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and **annexin** II (lipocortin 2). The cells within (II) express one or more polypeptides such as STRO-1, platelet-derived growth factor (PDGF) receptor, epidermal growth factor (EGF) receptor, CD10 and CD147.

INDEPENDENT CLAIMS are also included for the following:

(1) Distinguishing a population of small and rapidly self-RS cells from a population of large mMSC, by assessing whether at least 29 polypeptides are expressed in the cells in the RS cell population but are not expressed in the mMSC population, and further at least 9 polypeptides are expressed in the population of MSC, but are not expressed in the population of RS cells, where the RS cells are 7 microns in diameter and the cells within the MSC cell population are 15-50 microns in diameter; and

(2) A population of small and rapidly RS cells and mMSC identified by the above method.

ACTIVITY - None given.

MECHANISM OF ACTION - Cell and gene therapy.

No supporting data is given.

USE - The method is useful for distinguishing a population of small and rapidly self-RS cells from a population of large mMSC (claimed). The two classes of bone marrow stem cells, small rapidly self-renewing stem cells and large more mature marrow stromal cells are useful in cell and gene therapy.

Dwg.0/4

ACCESSION NUMBER: 2003-328406 [31] WPIDS  
DOC. NO. CPI: C2003-085353  
TITLE: Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .  
DERWENT CLASS: B04 D16  
INVENTOR(S): COLTER, D C; PROCKOP, D J; SEKIYA, I  
PATENT ASSIGNEE(S): (COLT-I) COLTER D C; (PROC-I) PROCKOP D J; (SEKI-I) SEKIYA I  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002168765	A1	20021114	(200331)*		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002168765	A1	US 2001-816182	20010323

PRIORITY APPLN. INFO: US 2001-816182 20010323

L5 ANSWER 5 OF 5 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related to **annexin** proteins.

AN 1999-337419 [28] WPIDS

AB WO 9921980 A UPAB: 19990719

NOVELTY - Isolated nucleic acid (I) encoding an **annexin** family member (II), i.e. a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR** in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the

following:

(1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an **annexin**, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect **annexin**-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of **annexin**, antibody to **annexin**, peptide or small molecule;

(7) pharmaceutical composition for reducing **MDR** comprising **annexin**-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS  
DOC. NO. NON-CPI: N1999-252873  
DOC. NO. CPI: C1999-099183  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins.  
DERWENT CLASS: B04 D16 S03  
INVENTOR(S): GEORGES, E; WANG, Y  
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y  
COUNTRY COUNT: 83  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE					
GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG					
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG					
US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026

CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

# FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> d his

(FILE 'HOME' ENTERED AT 17:11:31 ON 14 NOV 2003)

FILE 'MEDLINE, BIOSIS, DGENE, WPIDS' ENTERED AT 17:11:48 ON 14 NOV 2003

L1 9739 S ANNEXIN  
 L2 27718 S MDR OR MULTIDRUG RESISTANCE  
 L3 59 S L2 AND L1  
 L4 975 S ANNEXIN I  
 L5 5 S L4 AND L3

=> d l3 ti abs ibib 50-59

L3 ANSWER 50 OF 59 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
 TI 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB  
 carcinoma cell lines by apoptosis.  
 AB The aim of this study was to determine the mechanism of cell death  
 associated with the preferential killing of multidrug-resistant (**MDR**)  
 cells by the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in  
 a range of **MDR** human KB carcinoma cell lines selected in  
 different drugs. The D10 values for KB-V1, KB-C1 and KB-A1 (selected in  
 vinblastine, colchicine and doxorubicin respectively) were 1.74, 1.04 and  
 0.31 mm, respectively, compared with 4.60 mm for the parental cell line  
 (KB-3-1). The mechanism of cell death was identified as apoptosis, based  
 on nuclear morphology, **annexin** V binding and poly(ADP-ribose)  
 polymerase (PARP) cleavage. 2DG induced apoptosis in the three **MDR**  
 cell lines in a dose- and time-dependent manner and did not induce  
 necrosis. PARP cleavage was detected in KB-C1 cells within 2 h of  
 exposure to 50 mm 2DG and slightly later in KB-A1 and KB-V1 cells. The  
 relative levels of 2DG sensitivity did not correlate with the levels of  
**multidrug resistance** or with the reduced levels of the  
 glucose transporter GLUT-1 in these cells. We speculate that a  
 2DG-stimulated apoptotic pathway in **MDR** KB cells differs from  
 that in normal KB cells.

ACCESSION NUMBER: 1999:53368 BIOSIS  
 DOCUMENT NUMBER: PREV199900053368  
 TITLE: 2-Deoxy-D-glucose preferentially kills multidrug-resistant  
 human KB carcinoma cell lines by apoptosis.  
 AUTHOR(S): Bell, S. E.; Quinn, D. M.; Kellett, G. L.; Warr, J. R.  
 [Reprint author]  
 CORPORATE SOURCE: Dep. Biology, University York, P.O. Box 373, York YO10 5YW,  
 UK  
 SOURCE: British Journal of Cancer, (Dec., 1998) Vol. 78, No. 11,  
 pp. 1464-1470. print.  
 CODEN: BJCAAI. ISSN: 0007-0920.  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 10 Feb 1999  
 Last Updated on STN: 10 Feb 1999

L3 ANSWER 51 OF 59 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
TI Short course infusional idarubicin plus intermittent cytarabine and  
etoposide for refractory hematologic malignancies: Clinical and  
preliminary pharmacological results.  
AB Background and Objective. Idarubicin (IDA) is relatively immune to the  
**multidrug resistance** P-gp mechanism that is frequently  
expressed in recurrent and refractory hematologic malignancies. Owing to  
rapid metabolism in vivo, a continuous infusion (CI) of IDA might prolong  
exposure time to the parent drug rather than its more P-gp susceptible  
alcohol metabolite. For this reason we developed a brief retreatment  
schedule incorporating CI IDA in order to obtain clinical as well as  
preliminary pharmacological data in patients with refractory leukemias and  
lymphomas. Design and Methods. Eligible patients had either  
advanced-stage acute myeloid or lymphoid leukemias (AML, ALL) or  
high-grade non-Hodgkin's lymphomas (NHL) which failed curative-intent  
frontline or salvage regimens in use at our institution during the study  
period (July-October 1992). CI IDA 5 mg/m<sup>2</sup>/d was employed together with  
intermittent (every 8 hours) intermediate-dose cytarabine (500 mg/m<sup>2</sup>) and  
etoposide (200 Mg/M<sup>2</sup>); all drugs were given for 2-4 days. A preliminary  
pharmacokinetic evaluation of CI IDA was carried out in three patients,  
including a comparison with bolus delivery in one. The in vitro effects  
of CI-type vs bolus-type IDA delivery in terms of intracellular IDA  
accumulation and related pro-apoptotic activity were assessed in P-gp- and  
P-gp+ human leukemic CEM cells by means of cytofluorimetry (IDA  
fluorescence Intensity = FI, **annexin V** expression), with and  
without the addition of P-gp inhibitor cyclosporin A (CsA). Results.  
Complete (2) or partial (4) responses were achieved in a total of 12  
patients (17% and 33%, respectively), despite prior treatments with  
anthracyclines (100% of cases) and cytarabine-etoposide (33% of cases).  
Hematological toxicity caused the duration of treatment to be reduced from  
4 days to 2 days after the first 4 patients. The procedural death rate  
was 42% (5/12), which was probably related in part to the sum of adverse  
prognostic characteristics: median patient age 55 years, two-thirds of  
cases having previously failed second/third-line regimens. The  
pharmacokinetic study showed an increased plasma AUC value with CI IDA in  
one patient (2.9-fold increase vs bolus delivery) due to the prolonged  
presence of low IDA plasma levels (10-20 ng/mL vs 50 ng/mL), as seen in  
two other cases as well. On the other hand, the in vitro study did not  
prove to be in favor of CI IDA because the R threshold (>1500 units)  
associated with increased apoptosis of P-gp, cells (>10%) was achieved  
only with bolus-type IDA exposure (50 ng/mL for 30') plus CsA.  
Interpretation and conclusions. This short regimen demonstrated activity  
against end-stage leukemias and lymphomas and might prove to be more  
effective and less toxic in younger patients and in those with less  
advanced disease. In view of the results from plasma pharmacokinetics and  
in vitro intracellular IDA accumulation and apoptosis assays in  
lymphoblastic CEM cells, CI IDA 5 mg/m<sup>2</sup>/day may not represent a better  
therapeutic option than a rapid bolus injection, particularly in P-gp+  
neoplasms. If obtaining an adequate intracellular drug concentration is  
the primary treatment goal, a higher CI IDA dosage, the addition of a P-gp  
down-regulator such as CsA and others, and an in vivo study focusing on  
tumor samples from patients could all be helpful.

ACCESSION NUMBER: 1998:217080 BIOSIS

DOCUMENT NUMBER: PREV199800217080

TITLE: Short course infusional idarubicin plus intermittent  
cytarabine and etoposide for refractory hematologic  
malignancies: Clinical and preliminary pharmacological  
results.

AUTHOR(S): Bassan, Renato [Reprint author]; Chiodini, Barbara;  
Zucchetti, Massimo; Lerede, Teresa; Cornelli, Pier Emilio;  
Cortelazzo, Sergio; Barbui, Tiziano

CORPORATE SOURCE: Div. Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24100  
Bergamo, Italy

SOURCE: Haematologica, (Jan., 1998) Vol. 83, No. 1, pp. 27-33.

print.  
CODEN: HAEMAX. ISSN: 0390-6078.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 11 May 1998  
Last Updated on STN: 11 May 1998

L3 ANSWER 52 OF 59 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
TI THE 1991 MERCK FROSST AWARD **MULTIDRUG RESISTANCE** IN  
SMALL CELL LUNG CANCER.  
AB The two-year survival rate of patients with small cell lung cancer is less than 10%. The major reason for this poor outcome is the development of drug resistance. Panels of small cell lung cancer cell lines have been established, providing models for the study of drug resistance in this tumour. One such model is the doxorubicin-selected H69AR cell line. H69AR displays the typical **multidrug resistance** phenotype in that it is cross-resistant to anthracyclines, Vinca alkaloids (e.g., vinblastine) and epipodophyllotoxins (e.g. VP-16). However, H69AR cells do not overexpress P-glycoprotein, the membrane drug efflux pump frequently found on multidrug resistant cells. Some alterations in glutathione levels and associated enzyme activities were found but the data do not support the notion that enhanced drug detoxication is involved in H69AR cell resistance. Fewer drug-induced DNA strand breaks, reduced levels of topoisomerase II, and reduced formation of drug-stabilized DNA/topoisomerase II complexes were observed in H69AR cells. These data implicate topoisomerase II in the resistance phenotype of H69AR cells, but cannot explain H69AR cell resistance to the Vinca alkaloids, which do not have topoisomerase II as a target. Monoclonal antibodies against antigens overexpressed on H69AR cells have been derived and four have been characterized. Immunoscreening of an H69AR cDNA expression library was allowed the identification of one of these antigens as p36 (**annexin II**), a Ca<sup>2+</sup>/phospholipid binding protein. Chemosensitizers and novel xenobiotics have been examined for their ability to circumvent the drug resistance of H69AR cells. The limited success of these investigations suggests that innovative approaches may be required. In conclusion, the data obtained with H69AR and other models of small cell lung cancer indicate that multiple mechanisms contribute to drug resistance in this disease.

ACCESSION NUMBER: 1992:282892 BIOSIS  
DOCUMENT NUMBER: PREV199294007542; BA94:7542  
TITLE: THE 1991 MERCK FROSST AWARD **MULTIDRUG RESISTANCE** IN SMALL CELL LUNG CANCER.  
AUTHOR(S): COLE S P C [Reprint author]  
CORPORATE SOURCE: CANCER RES LAB, QUEEN'S UNIV, KINGSTON, ONT, CANADA K7L 3N6  
SOURCE: Canadian Journal of Physiology and Pharmacology, (1992)  
Vol. 70, No. 3, pp. 313-329.  
CODEN: CJPPA3. ISSN: 0008-4212.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 10 Jun 1992  
Last Updated on STN: 9 Aug 1992

L3 ANSWER 53 OF 59 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN  
TI Modulating or assessing **multidrug resistance** related to **annexin** proteins  
AN AAY08412 Protein DGENE  
AB This invention describes a novel human **annexin** family member, P-40 (also known as **annexin I**) which is a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR** in a cell. Antisense P-40 sequences are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of the P-40 nucleic acid, or related RNA, is used to detect cancer (or pathogens) with **MDR**,



or susceptibility. P-40 nucleic acid can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing the nucleic acid expression in plants may be used to develop specific resistance. The products of the invention have antitumour and antifungal activity.

ACCESSION NUMBER: AAY08412 Protein DGENE  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins  
INVENTOR: Georges E; Wang Y  
PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.  
PATENT INFO: WO 9921980 A1 19990506 63p  
APPLICATION INFO: WO 1998-CA992 19981026  
PRIORITY INFO: CA 1997-2219299 19971024  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-337419 [28]  
CROSS REFERENCES: N-PSDB: AAX57357; AAX57358  
DESCRIPTION: Human p-40/**annexin** I protein.

L3 ANSWER 54 OF 59 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related to **annexin** proteins

AN AAX57358 DNA DGENE

AB This invention describes a novel human **annexin** family member, P-40 (also known as **annexin** I) which is a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR** in a cell. Antisense P-40 sequences are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of the P-40 nucleic acid, or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. P-40 nucleic acid can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing the nucleic acid expression in plants may be used to develop specific resistance. The products of the invention have antitumour and antifungal activity.

ACCESSION NUMBER: AAX57358 DNA DGENE  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins  
INVENTOR: Georges E; Wang Y  
PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.  
PATENT INFO: WO 9921980 A1 19990506 63p  
APPLICATION INFO: WO 1998-CA992 19981026  
PRIORITY INFO: CA 1997-2219299 19971024  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-337419 [28]  
CROSS REFERENCES: P-PSDB: AAY08413  
DESCRIPTION: Human p-40/**annexin** I antisense DNA.

L3 ANSWER 55 OF 59 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

TI Modulating or assessing **multidrug resistance** related to **annexin** proteins

AN AAX57357 DNA DGENE

AB This invention describes a novel human **annexin** family member, P-40 (also known as **annexin** I) which is a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR** in a cell. Antisense P-40 sequences are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of the P-40 nucleic acid, or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. P-40 nucleic acid can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing the nucleic acid expression in plants may be used to develop specific resistance. The products of the invention have antitumour and antifungal

activity.  
 ACCESSION NUMBER: AAX57357 DNA DGENE  
 TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins  
 INVENTOR: Georges E; Wang Y  
 PATENT ASSIGNEE: (UYMC-N)UNIV MCGILL.  
 PATENT INFO: WO 9921980 A1 19990506 63p  
 APPLICATION INFO: WO 1998-CA992 19981026  
 PRIORITY INFO: CA 1997-2219299 19971024  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 OTHER SOURCE: 1999-337419 [28]  
 CROSS REFERENCES: P-PSDB: AAY08412  
 DESCRIPTION: Human p-40/**annexin** I DNA.

L3 ANSWER 56 OF 59 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
 TI Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .  
 AN 2003-328406 [31] WPIDS  
 AB US2002168765 A UPAB: 20030516  
 NOVELTY - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC), is new. The cells within (I) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and **annexin** II (lipocortin 2).

DETAILED DESCRIPTION - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and **annexin** II (lipocortin 2). The cells within (II) express one or more polypeptides such as STRO-1, platelet-derived growth factor (PDGF) receptor, epidermal growth factor (EGF) receptor, CD10 and CD147.

INDEPENDENT CLAIMS are also included for the following:

(1) Distinguishing a population of small and rapidly self-RS cells from a population of large mMSC, by assessing whether at least 29 polypeptides are expressed in the cells in the RS cell population but are not expressed in the mMSC population, and further at least 9 polypeptides are expressed in the population of MSC, but are not expressed in the population of RS cells, where the RS cells are 7 microns in diameter and the cells within the MSC cell population are 15-50 microns in diameter; and

(2) A population of small and rapidly RS cells and mMSC identified by the above method.

ACTIVITY - None given.

MECHANISM OF ACTION - Cell and gene therapy.

No supporting data is given.

USE - The method is useful for distinguishing a population of small and rapidly self-RS cells from a population of large mMSC (claimed). The two classes of bone marrow stem cells, small rapidly self-renewing stem cells and large more mature marrow stromal cells are useful in cell and gene therapy.

Dwg.0/4

ACCESSION NUMBER: 2003-328406 [31] WPIDS  
 DOC. NO. CPI: C2003-085353  
 TITLE: Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): COLTER, D C; PROCKOP, D J; SEKIYA, I  
 PATENT ASSIGNEE(S): (COLT-I) COLTER D C; (PROC-I) PROCKOP D J; (SEKI-I)

SEKIYA I  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002168765	A1	20021114	(200331)*		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002168765	A1	US 2001-816182	20010323

PRIORITY APPLN. INFO: US 2001-816182 20010323

L3 ANSWER 57 OF 59 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
TI New conjugated polymer tag complexes, useful for detecting analytes in a sample, have fluorescent optical labels attached to amino acid monomer units.  
AN 2001-367253 [38] WPIDS  
AB WO 200127625 A UPAB: 20010711  
NOVELTY - Water soluble polymer (A) of known composition and sequence linked to and selectively cleaved from a solid support comprises a cleavage segment next to the support, a second segment able to covalently couple to a tag, and a third segment able to covalently bond to an analyte-binding species or an analyte.  
DETAILED DESCRIPTION - Water soluble polymer (A) of known composition and sequence linked to and selectively cleaved from a solid support comprises a cleavage segment next to the support made of at least one monomer unit, a second segment of at least one monomer unit linked to a reactive functionality able to covalently couple to a tag, and a third segment comprising at least one monomer unit linked to a reactive functionality able to covalently bond to an analyte-binding species or an analyte.  
INDEPENDENT CLAIMS are also included for:  
(1) a tagged water soluble polymer (B) linked to and selectively cleaved from a solid support comprises a cleavage segment next to the support, a second segment able to covalently couple to a tag, and a third segment able to covalently bond to an analyte-binding species or an analyte;  
(2) polymer (B) of formula (III) cleaved from the solid support;  
(3) preparation of a conjugate of an analyte-binding species and a tagged water soluble polymer comprising: synthesis of a water soluble polymer linked to a solid support; when necessary, specifically reacting at least one monomer unit with one or more tags; specifically reacting at least one monomer unit with an analyte-binding species; and selectively cleaving the polymer from the solid support;  
(4) preparation of a tagged water soluble polymer comprising at least two monomer units linked to a reactive functionality and at least one spacer unit and at least one monomer unit linked to an optical label capable of emitting and/or absorbing light, comprising: reacting a monomer containing 2-3 reactive functionalities of which all but one are protected with a solid support; deprotecting; reacting the product with a second monomer containing 2-3 reactive functionalities of which all but one are protected; deprotecting; repeating with further monomer units; cleaving polymer from support; and deprotecting reactive functionalities, where at least one monomer is linked to an optical label capable of absorbing and/or emitting light between 200-1400 nm;  
(5) a method for detecting an analyte by linking the analyte to an analyte-binding species linked to polymer (B); and  
(6) preparation of (III) by modeling a sequence of amino acids to optimize distance and geometry between fluorescent optical labels,

synthesizing polymers by combinatorial methods, screening polymers by fluorescence and/or luminescence spectra for maximum desired emission to determine potential candidates to be optical labels in tagged peptides, synthesizing (A), cleaving polymer from the support, coupling an analyte binding species, cleaving optically labeled polymer, and utilizing the polymer conjugate.

USE - To detect an analyte in a sample by fluorescence (claimed).

Dwg.0/0

ACCESSION NUMBER: 2001-367253 [38] WPIDS  
DOC. NO. NON-CPI: N2001-267990  
DOC. NO. CPI: C2001-112561  
TITLE: New conjugated polymer tag complexes, useful for detecting analytes in a sample, have fluorescent optical labels attached to amino acid monomer units.  
DERWENT CLASS: A23 A96 B04 D16 S03  
INVENTOR(S): FRANSON, R C; LEIF, R C; VALLARINO, L M; VALLARINO, L  
PATENT ASSIGNEE(S): (FRAN-I) FRANSON R C; (LEIF-I) LEIF R C; (VALL-I) VALLARINO L M; (VALL-I) VALLARINO L  
COUNTRY COUNT: 22  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----					
WO 2001027625	A1	20010419	(200138)*	EN	104
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA CH DE FI GB JP US					
EP 1221052	A1	20020710	(200253)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----			
WO 2001027625	A1	WO 2000-US27787	20001007
EP 1221052	A1	EP 2000-968871	20001007
		WO 2000-US27787	20001007

#### FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----		
EP 1221052	A1 Based on	WO 2001027625

PRIORITY APPLN. INFO: US 1999-158718P 19991008

L3 ANSWER 58 OF 59 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
TI New spectrofluorometrically detectable luminescent composition, useful for detecting e.g. vitamins, hormones, pharmaceuticals, drugs, pesticides, proteins or nucleic acids.

AN 2000-505733 [45] WPIDS

AB WO 200042048 A UPAB: 20021014

NOVELTY - A novel spectrofluorimetrically detectable luminescent composition comprises water, a micelle-producing amount of at least one surfactant, at least one energy transfer acceptor lanthanide element macrocycle compound (EALM) having an emission spectrum peak of 500-950 nm, and at least one energy transfer donor compound of yttrium or a 3-valent lanthanide element having atomic number 59-71.

DETAILED DESCRIPTION - A novel spectrofluorimetrically detectable luminescent composition comprises water, a micelle-producing amount of at least one surfactant, at least one energy transfer acceptor lanthanide element macrocycle compound (EALM) (at least  $1 \times 10^{-10}$  moles/liter) having an emission spectrum peak of 500-950 nm, and a luminescence-enhancing amount of at least one energy transfer donor compound of yttrium or a 3-valent lanthanide element having atomic number 59-71, provided that the

lanthanide element of the macrocycle compound and the lanthanide element of the energy transfer donor compound are not identical.

An INDEPENDENT CLAIM is also included for a method for analysis of a sample containing or suspected of containing at least one analyte, frequently a biologically active compound, the method comprising:

(a) contacting the sample with a functionalized complex of a metal M, where M is a metal ion selected from a lanthanide having atomic number 57-71, and actinide having atomic number 89-103, and yttrium (III) having atomic number 39; in a reaction medium under binding conditions, whereby the analyte when present either interacts with the complex to form a conjugate or competes for interaction with a binding material specific for interaction with the complex and with the analyte;

(b) adding to the reaction medium a luminescence-enhancing amount of at least one energy transfer donor compound of yttrium or a 3-valent lanthanide element having atomic number 59-71, provided that the lanthanide element of the macrocycle compound and a lanthanide element of the energy transfer donor compound are not identical;

(c) subjecting the reaction medium to excitation energy in the range of 200-400 nm, whereby enhanced luminescence in the range of 500-950 nm is generated;

(d) monitoring the luminescence of the reaction medium to measure in the sample: (i) the presence and/or concentration of the conjugate; (ii) the presence and/or concentration of the product of the interaction of the complex with the binding material; and/or (iii) the presence and/or concentration of the product of the interaction of the conjugate with the binding material.

USE - The method can be used for the detection of analytes such as vitamins, vitamin precursors, and vitamin metabolites including retinal, vitamin K, cobalamin, biotin folate; hormones and related compounds including steroid hormones including estrogen, corticosterone, testosterone, ecdysone; amino acid derived hormones including thyroxine, epinephrine; prostaglandins; peptide hormones including oxytocin, somatostatin; pharmaceuticals including aspirin, penicillin, hydrochlorothiazide; nucleic acid constituents including natural and synthetic nucleic acid bases including cytosine, thymine, adenine, guanine, uracil, derivatives of the bases including 5-bromouracil, natural and synthetic nucleosides and deoxynucleosides including 2-deoxyadenosine, 2-deoxycytidine, 2-deoxythymidine, 2-deoxyguanosine, 5-bromo-2-deoxyuridine, adenosine, cytidine, uridine, guanosine, 5-bromouridine; drugs of abuse including cocaine, tetrahydrocannabinol; histological stains including fluorescein, DA PI, pesticides including digitoxin; and miscellaneous haptens including diphenylhydantoin, quinidine, RDX; polyaminoacids, polypeptides, proteins, polysaccharides, nucleic acids, glycosaminoglycans, glycoproteins, ribosomes, and proteins and their combinations including albumins, globulins, hemoglobin, staphylococcal protein A, alpha-feto-protein, retinal-binding protein, avidin, streptavidin, C-reactive protein, collagen, keratin; immunoglobulins including IgG, IgM, AgA, IgE; hormones including lymphokines, follicle stimulating hormone, and thyroid stimulating hormone; enzymes including trypsin, peptide, reverse transcriptases; cell surface antigens on T- and B-lymphocytes, i.e. CD-4, CD-8, CD-20 proteins, and the leukocyte cell surface antigens; blood group antigens including A, B and Rh; major histocompatibility antigens both of class 1 and 2; hormone receptors including estrogen receptor, progesterone receptor, and glucocorticoid receptor; cell cycle associated proteins including protein kinases, cyclins, PCNA, p53; antigens associated with cancer diagnosis and therapy including BRCA(s) carcinoembryonic antigen, HPV 16, HPV 18, **MDR**, c-neu, tumor suppressor proteins, p53 and retinalblastoma; apoptosis related markers including **annexin V**, bak, bcl-2, fas caspases, nuclear matrix protein, cytochrome c, nucleosome; toxins including cholera toxin, diphtheria toxin, botulinum toxin, snake venom toxins, tetrodotoxin, saxitoxin; lectins including concanavalin, wheat germ agglutinin, soy bean agglutinin; polysialic acids including chitin; polynucleotides including RNAs including segments of the HIV genome, human

hemoglobin A, mRNA, DNAs including chromosome specific sequences, centromeres, telomere specific sequences, single copy sequences from normal tissues, or single copy sequences from tumors (claimed). The compositions can also be used in analytical cytology, histological staining and imaging processing.

ADVANTAGE - The compositions do not require the prior dissociation of the luminescence-enhanced complex before measuring its emission spectrum, and do not require time-gated detection systems. Using the method, 2 different analytes can be measured in the presence of one another.

Dwg.0/15

ACCESSION NUMBER: 2000-505733 [45] WPIDS  
DOC. NO. CPI: C2000-151733  
TITLE: New spectrofluorometrically detectable luminescent composition, useful for detecting e.g. vitamins, hormones, pharmaceuticals, drugs, pesticides, proteins or nucleic acids.  
DERWENT CLASS: B02 B04 D16  
INVENTOR(S): LEIF, R C; VALLARINO, L M; VALLARINO, L  
PATENT ASSIGNEE(S): (LEIF-I) LEIF R C; (VALL-I) VALLARINO L M; (VALL-I) VALLARINO L  
COUNTRY COUNT: 22  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000042048	A1	20000720	(200045)*	EN	94
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA CH DE FI GB JP US					
EP 1150985	A1	20011107	(200168)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
US 6340744	B1	20020122	(200208)		
US 2002132992	A1	20020919	(200264)		

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000042048	A1	WO 2000-US1211	20000118
EP 1150985	A1	EP 2000-905653	20000118
		WO 2000-US1211	20000118
US 6340744	B1 Provisional	US 1999-116316P	19990119
		US 2000-484670	20000118
US 2002132992	A1 Provisional	US 1999-116316P	19990119
	Cont of	US 2000-484670	20000118
		US 2001-10597	20011206

#### FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1150985	A1 Based on	WO 2000042048
US 2002132992	A1 Cont of	US 6340744

PRIORITY APPLN. INFO: US 2000-484670 20000118; US 1999-116316P 19990119; US 2001-10597 20011206

L3 ANSWER 59 OF 59 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
TI Modulating or assessing **multidrug resistance** related to **annexin** proteins.  
AN 1999-337419 [28] WPIDS  
AB WO 9921980 A UPAB: 19990719  
NOVELTY - Isolated nucleic acid (I) encoding an **annexin** family member (II), i.e. a member of the **MDR (multidrug resistance)** gene family, for assessing or modulating **MDR**

in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an **annexin**, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;
- (2) kits for this method;
- (3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;
- (4) cells containing this vector;
- (5) a method for identifying compounds that affect **annexin**-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;
- (6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of **annexin**, antibody to **annexin**, peptide or small molecule;
- (7) pharmaceutical composition for reducing **MDR** comprising **annexin**-based **MDR**-affecting compound and a carrier; and
- (8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS  
DOC. NO. NON-CPI: N1999-252873  
DOC. NO. CPI: C1999-099183  
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins.  
DERWENT CLASS: B04 D16 S03  
INVENTOR(S): GEORGES, E; WANG, Y  
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y  
COUNTRY COUNT: 83  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)	* EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

# FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----	-----	-----
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> d his

(FILE 'HOME' ENTERED AT 17:11:31 ON 14 NOV 2003)

FILE 'MEDLINE, BIOSIS, DGENE, WPIDS' ENTERED AT 17:11:48 ON 14 NOV 2003

L1 9739 S ANNEXIN  
L2 27718 S MDR OR MULTIDRUG RESISTANCE  
L3 59 S L2 AND L1  
L4 975 S ANNEXIN I  
L5 5 S L4 AND L3

=> d l3 ti abs ibib 1-15

L3 ANSWER 1 OF 59 MEDLINE on STN  
TI In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.  
AB The biological activity of MEN 11079, a new daunorubicin analogue with a fluorine atom in C(8) of ring A, was investigated in the human leukemic cell lines K-562 and in mononuclear cells (MNCs) of 40 patients with acute myeloid leukemia (AML) and the activity compared to two well-characterized anthracyclines, idarubicin (IDA) and doxorubicin (DOXO). IDA and MEN 11079 were more active than DOXO in cytotoxicity tests (WST-1 assay). IDA and MEN 11079 ID(50) values were also significantly different from each other (K-562: P=0.038; MNCs: P=0.003). Moreover, the range was 0.002-4.300 microM for IDA and 0.002-0.670 microM for MEN 11079, in the MNCs. Therefore, the latter appeared to assure a smaller variability of response in the AML cells. Apoptosis assays (performed using Annexin-V assay and propidium iodide) and cell cycle studies demonstrated that the MEN 11079 effective concentration was 10-fold lower than the DOXO and IDA ones. MDR (Pgp and MRP1 proteins), as measured by semiquantitative RT-PCR, cytofluorimetric and functional analysis of proteins, was similarly elicited by IDA and MEN 11079. In conclusion, the response of the cells to the new anthracycline indicates that there is greater cytotoxic activity of this molecule than IDA and DOXO. Its narrower ID(50) range may allow for a more predictable response in the clinical setting.

ACCESSION NUMBER: 2003468952 MEDLINE  
DOCUMENT NUMBER: 22804432 PubMed ID: 12921951  
TITLE: In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.  
AUTHOR: Biscardi Monica; Caporale Roberto; Pagliai Gabriella; Leoni Franco; Bernabei Pietrantonio; Santini Valeria; Ciolli Stefania; Grossi Alberto  
CORPORATE SOURCE: U.O. Hematology, Azienda Ospedaliera Careggi, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.  
SOURCE: LEUKEMIA RESEARCH, (2003 Dec) 27 (12) 1125-34.  
Journal code: 7706787. ISSN: 0145-2126.  
PUB. COUNTRY: England: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)



LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200311  
ENTRY DATE: Entered STN: 20031009  
Last Updated on STN: 20031105  
Entered Medline: 20031104

L3 ANSWER 2 OF 59 MEDLINE on STN

TI Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation.

AB Therapeutic resistance remains an unresolved problem in the clinical management of human prostate cancer (PC). Despite initial positive response to androgen ablation therapy (AAT), virtually all PC patients will relapse due to acquisition of hormone refractory disease and selective outgrowth of tumor cells with **multidrug resistance** phenotype. We here provide the first experimental evidence that restoring a functional androgen receptor (AR) in the androgen-independent prostate cancer PC3 cells enhances their sensitivity to growth arrest and suppresses their colony-forming ability in response to paclitaxel and gamma-irradiation. Furthermore, functional AR increases the susceptibility of these cells to the apoptotic potentials of therapeutic agents, as evidenced by an increase in caspase activity, **annexin V** binding, and internucleosomal DNA fragmentation, by inducing caspase activation. The abrogation of the cytotoxic effects by 4-hydroxyflutamide suggests a crucial role for AR activation in enhancing the therapeutic sensitivity of these cells in a ligand-independent fashion. Our data thus demonstrate that a functional AR is a prerequisite for effective therapeutic response and that aberrant expression or blockade by AAT may trigger pathways leading to emergence of PC cells with therapeutic resistance phenotype. Since the mainstay of primary therapy for PC has been AAT by pharmaco-therapeutic or surgical means, this study thus provides a new frontier for revising the AAT therapeutic strategy in conjunction with radiation and/or chemotherapeutic agents.

ACCESSION NUMBER: 2003438023 IN-PROCESS

DOCUMENT NUMBER: 22859441 PubMed ID: 13679064

TITLE: Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation.

AUTHOR: Davis Rodney; Jia Dingwu; Cinar Bekir; Sikka Suresh C; Moparty Krishnarao; Zhou Haiyen E; Chung Leland W; Agrawal Krishna C; Abdel-Mageed Asim B

CORPORATE SOURCE: Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.

SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2003 Oct 3) 309 (4) 937-45.

Journal code: 0372516. ISSN: 0006-291X.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals

ENTRY DATE: Entered STN: 20030923

Last Updated on STN: 20031018

L3 ANSWER 3 OF 59 MEDLINE on STN

TI The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer.

AB OBJECTIVE: To study the relationship between the expression of drug resistance genes and the results of drug sensitivity test. METHODS: Surgical or biopsy specimens from 48 patients with non-small cell lung cancer (NSCLC) were measured for drug sensitivity by **Annexin V** combined with PI using flow cytometry. The drug resistance genes **MDR(1)**, **GST-pi** and **MPR** were measured by RT-PCR. The relationship between expression of drug resistance gene mutations and the drug sensitivity of lung cancer was analyzed. RESULTS: The anti-tumor

cytotoxicity of MMC, DDP, VDS, NVB, TAX, GEM, VP-16 and VCR were measured, and their respective tumor inhibition rates were (10.3 +/- 17.1)%, (20.7 +/- 22.2)%, (5.6 +/- 14.9)%, (7.9 +/- 16.2)%, (15.7 +/- 21.8)%, (11.2 +/- 13.8)%, (9.7 +/- 20.1)%, and (4.7 +/- 8.7)%. The positive rates of **MDR**(1), MRP and GST-pi expression were 67% (32/48), 42% (20/48), and 48% (23/48) respectively. There was no association between the expression of drug resistance genes MRP and GST-pi and the pathology or the stage of lung cancer. Interestingly, the over-expression of MRP was related to drug resistance to NVB, VDS and MMC; while the over-expression of GST-pi was related to resistance to DDP. No relationship was found between **MDR**(1) over-expression and drug resistance. CONCLUSION: The expression of some drug resistance genes is related to drug sensitivity test. The detection of the genes may be clinically useful in the administration of chemotherapy.

ACCESSION NUMBER: 2003111698 MEDLINE  
DOCUMENT NUMBER: 22512168 PubMed ID: 12622891  
TITLE: The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer.  
AUTHOR: Han Baohui; Liao Meilin; Su Jianzhong; Feng Jiuxian; Wang Enzhong; Dong Qianggang  
CORPORATE SOURCE: Department of Pulmonology, Shanghai Chest Hospital, Shanghai 200030, China.  
SOURCE: CHUNG-HUA CHIEH HO HO HU HSI TSA CHIH CHINESE JOURNAL OF TUBERCULOSIS AND RESPIRATORY DISEASES, (2002 Dec) 25 (12) 727-31.  
Journal code: 8712226. ISSN: 1001-0939.  
PUB. COUNTRY: China  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: Chinese  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200308  
ENTRY DATE: Entered STN: 20030308  
Last Updated on STN: 20030819  
Entered Medline: 20030818

L3 ANSWER 4 OF 59 MEDLINE on STN  
TI Interaction between various resistance modifiers and apoptosis inducer 12H-benzo[alpha]phenothiazine.  
AB The effect of some resistance modifiers on apoptosis induction by a benzo[alpha]phenothiazine derivative was studied on the L5178Y mouse lymphoma cells (parent) and its multidrug resistant (**MDR**) subline. For evaluation of apoptosis the cells were stained with FITC-labelled **annexin V** and propidium iodide and the results were analysed by flow cytometry. 12H-benzo[alpha]phenothiazine [M627] induced apoptosis both in the parent cells and in the **MDR** cells. The apoptosis induction by [M627] was not affected significantly by post- or pre-treatment with resistance modifiers, while in the cells treated by (+/-)-verapamil before and after apoptosis induction with [M627], the apoptosis was somewhat higher. The resistance modifier compounds alone also induced apoptosis and it was slightly higher in the parent cells than its **MDR1/A** gene-transformed subline.

ACCESSION NUMBER: 2003024018 MEDLINE  
DOCUMENT NUMBER: 22418380 PubMed ID: 12530005  
TITLE: Interaction between various resistance modifiers and apoptosis inducer 12H-benzo[alpha]phenothiazine.  
AUTHOR: Mucsi Ilona; Varga Andreas; Kawase Masami; Motohashi Noboru; Molnar Joseph  
CORPORATE SOURCE: Department of Medical Microbiology, Faculty of General Medicine, University of Szeged, Hungary.  
SOURCE: ANTICANCER RESEARCH, (2002 Sep-Oct) 22 (5) 2833-6.  
Journal code: 8102988. ISSN: 0250-7005.  
PUB. COUNTRY: Greece  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200302  
ENTRY DATE: Entered STN: 20030118  
Last Updated on STN: 20030221  
Entered Medline: 20030220

L3 ANSWER 5 OF 59 MEDLINE on STN

TI The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.

AB Ras-homologous GTPases are involved in the regulation of genotoxic stress-induced gene expression and cell death. Since they need C-terminal isoprenylation for correct intracellular localization and function, we investigated whether depletion of cells from isopren precursor moieties using the HMG-CoA reductase inhibitor lovastatin affects cellular sensitivity to DNA damaging drugs. Here we show that lovastatin renders cells highly resistant to the tumor-therapeutic compound doxorubicin. Desensitization by lovastatin was reverted by co-treatment with GGPP indicating that inhibition of protein geranylgeranylation is involved in acquired doxorubicin resistance. Lovastatin does not influence cellular sensitivity to DNA damaging compounds such as cisplatin, methyl methanesulfonate and ionizing radiation. The frequency of apoptotic cell death induced by doxorubicin was not affected by lovastatin as shown by both **annexin V** and DNA fragmentation assay. However, lovastatin releases cells from doxorubicin induced G2 blockage. Furthermore, lovastatin protects cells from doxorubicin-induced DNA strand breakage without affecting drug uptake or the expression of **multidrug resistance** protein (**mdr-1**). Since lovastatin confers cross-resistance to the topoisomerase II specific inhibitor etoposide, we suggest desensitization by the statin to be related to topoisomerase II function. The finding that lovastatin renders cells resistant to doxorubicin and etoposide by reducing their genotoxic and cytotoxic effects might have clinical implications for cancer therapy.

ACCESSION NUMBER: 2002477340 MEDLINE  
DOCUMENT NUMBER: 22224508 PubMed ID: 12239596  
TITLE: The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.  
AUTHOR: Bardeleben Renate V; Dunkern Torsten; Kaina Bernd; Fritz Gerhard  
CORPORATE SOURCE: Division of Applied Toxicology, Institute of Toxicology, University of Mainz, D-55131 Mainz, Germany.  
SOURCE: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, (2002 Oct) 10 (4) 473-9.  
Journal code: 9810955. ISSN: 1107-3756.  
PUB. COUNTRY: Greece  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200303  
ENTRY DATE: Entered STN: 20020920  
Last Updated on STN: 20030312  
Entered Medline: 20030311

L3 ANSWER 6 OF 59 MEDLINE on STN

TI Modulation of the **multidrug resistance** of glioma by glutathione levels depletion--interaction with Tc-99m-Sestamibi and Tc-99m-Tetrofosmin.

AB We have investigated the effect of glutathione (GSH) depletion on the chemosensitivity of human malignant glioma cell lines: G111, G5 and G152. All the cell lines showed a multidrug resistant (**MDR**) phenotype associated with MRP1 expression, high intracellular levels of GSH, and depolarized plasma membranes. Tc-99m-Sestamibi (MIBI) and Tc-99m-Tetrofosmin (Tfos) were used for monitoring the **MDR** mechanisms. Modulation of GSH content was performed with

butoxysulfoximide (BSO) pre-treatment alone or in combination with GSH ethyl ester. MIBI and Tfos accumulation in the cells was inversely correlated to the GSH content, a higher accumulation was found after BSO pre-treatment and addition of GSH ethyl ester reversed this process. BSO could therefore play a role as a chemosensitizing drug and thus help to overcome **MDR**. However, higher accumulation of MIBI and Tfos was observed even in the sensitive cells suggesting another effect of BSO on the cell physiological characteristics. No sign of apoptosis has been found indicating a possible direct effect on the plasma membrane fluidity and permeability. MIBI and Tfos don't follow the expected behavior of a **MDR** probe in the glioma cells and given the particular morpho-physiological characteristics of these types of tumors, Tfos could be rather used as a marker of the tumor growth and proliferation.

ACCESSION NUMBER: 2002388439 MEDLINE  
DOCUMENT NUMBER: 22132687 PubMed ID: 12136521  
TITLE: Modulation of the **multidrug resistance** of glioma by glutathione levels depletion--interaction with Tc-99M-Sestamibi and Tc-99M-Tetrofosmin.  
AUTHOR: Perek Nathalie; Koumanov Francoise; Denoyer Delphine; Boudard Delphine; Dubois Francis  
CORPORATE SOURCE: Department of Biophysics and Image Treatment, Faculty of Medicine, Jacques Lisfranc, Saint Etienne, France.. nathalie.perek@univ-st-etienne.fr  
SOURCE: CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, (2002 Jun) 17 (3) 291-302.  
Journal code: 9605408. ISSN: 1084-9785.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200301  
ENTRY DATE: Entered STN: 20020725  
Last Updated on STN: 20030128  
Entered Medline: 20030127

L3 ANSWER 7 OF 59 MEDLINE on STN

TI Transport of phosphatidylserine via MDR1 (**multidrug resistance** 1)P-glycoprotein in a human gastric carcinoma cell line.

AB The ATP-binding cassette transporter **multidrug resistance** 1 P-glycoprotein (MDR1 Pgp) has been implicated with the transport of lipids from the inner to the outer leaflet of the plasma membrane. While this has been unambiguously shown for the fluorescent lipid analogues [N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]hexanoyl (C6-NBD)-phosphatidylcholine, -phosphatidylethanolamine, -sphingomyelin and -glucosylceramide, by using a novel approach we have now found significantly increased outward transport also for C6-NBD-phosphatidylserine (C6-NBD-PS) in EPG85-257 human gastric carcinoma cells overexpressing MDR1 (coding for MDR1 Pgp). The increased transport of C6-NBD-PS is mediated by MDR1 Pgp, shown by transport reduction nearly to the level of controls in the presence of MDR1 Pgp inhibitors [PSC 833, cyclosporin A and dextrageldipine hydrochloride (Dex)]. Addition of MK 571, a specific inhibitor of the **MDR** protein MRP1, does not decrease transport in either of the two cell lines. The plasma-membrane association of FITC-**annexin** V, a fluorescent protein conjugate binding PS, is significantly increased in MDR1-overexpressing cells as compared with controls, and can be reduced by an MDR1 Pgp inhibitor. This suggests that MDR1 Pgp transports endogenous PS, the lipid exhibiting the most pronounced transverse asymmetry in the plasma membrane.

ACCESSION NUMBER: 2002329193 MEDLINE  
DOCUMENT NUMBER: 22067080 PubMed ID: 12071854  
TITLE: Transport of phosphatidylserine via MDR1 (**multidrug resistance** 1)P-glycoprotein in a human gastric carcinoma cell line.

AUTHOR: Pohl Antje; Lage Hermann; Muller Peter; Pomorski Thomas; Herrmann Andreas  
CORPORATE SOURCE: Institute of Biology/Biophysics, Humboldt University Berlin, Invalidenstrasse 43, 10115 Berlin, Germany.  
SOURCE: BIOCHEMICAL JOURNAL, (2002 Jul 1) 365 (Pt 1) 259-68.  
Journal code: 2984726R. ISSN: 0264-6021.  
PUB. COUNTRY: England: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200207  
ENTRY DATE: Entered STN: 20020620  
Last Updated on STN: 20020727  
Entered Medline: 20020726

L3 ANSWER 8 OF 59 MEDLINE on STN

TI Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the rhodamine-c-kit(+)CD33(-)CD38(-) fraction of umbilical cord CD34(+) cells.  
AB OBJECTIVE: The study of hematopoietic stem cells (HSC) is limited by lack of specific markers for HSC. Rhodamine 123 (Rho) is one of the substrates of P-glycoprotein (Pgp), and the presence of active Pgp can be shown by the efflux of Rho. Rho can also be used to measure the mitochondrial transmembrane potential (energy state) of a cell. We reasoned that selection of hematopoietic progenitors using a combination of Rho efflux and phenotypic markers might be superior to use of phenotypic markers alone. MATERIALS AND METHODS: We used the myeloid-lymphoid initiating cell (ML-IC) assay as functional measure of primitive progenitors. Umbilical cord blood CD34(+)CD33(-)CD38(-), CD34(+)CD33(-)CD38(-)Rho(-), and CD34(+)CD33(-)CD38(-)Rho(-)c-kit(+) cells were sorted singly onto AFT024 feeders to assess their capacity to become ML-IC. RESULTS: The frequency of ML-IC in CD34(+)CD33(-)CD38(-)Rho(-) cells was significantly higher (15 +/- 0.4%) than that in CD34(+)CD33(-)CD38(-) cells (6.2 +/- 0.9%, p < 0.05). However, the frequency of long-term culture-initiating cells (LTC-IC) (17 +/- 3% vs 12 +/- 1.5%) and natural killer culture-initiating cells (NK-IC) (25 +/- 3% vs 20 +/- 4%) was similar in the two populations. Following the treatment of CD34(+)CD33(-)CD38(-)Rho(-) cells with verapamil, which blocks Pgp function, no increase in ML-IC was detected compared with CD34(+)CD33(-)CD38(-) cells (6 +/- 0.7%), suggesting that differences in the energy state, which is reflected by Rho staining after verapamil treatment, cannot be used as a criterion to identify human HSC. Further selection of CD34(+)CD33(-)CD38(-)Rho(-) cells based on expression of c-kit significantly increased the frequency of ML-IC, LTC-IC and NK-IC by 1.75-, 1.3-, and 1.8-fold, respectively. CONCLUSION: Combining the function of Pgp and phenotypic features of hematopoietic progenitors enriches the frequency of cord blood ML-IC to greater than 25%. Use of such enriched populations will allow us to characterize the biological behavior of human HSC.

ACCESSION NUMBER: 2002318669 MEDLINE  
DOCUMENT NUMBER: 22057778 PubMed ID: 12063025  
TITLE: Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the rhodamine-c-kit(+)CD33(-)CD38(-) fraction of umbilical cord CD34(+) cells.  
AUTHOR: Liu Hsingjin; Verfaillie Catherine M  
CORPORATE SOURCE: Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis 55455, USA.  
CONTRACT NUMBER: P01-CA-65493-6 (NCI)  
SOURCE: EXPERIMENTAL HEMATOLOGY, (2002 Jun) 30 (6) 582-9.  
Journal code: 0402313. ISSN: 0301-472X.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200207

ENTRY DATE: Entered STN: 20020614  
Last Updated on STN: 20021218  
Entered Medline: 20020710

L3 ANSWER 9 OF 59 MEDLINE on STN  
TI Induction of **multidrug resistance** in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.  
AB PURPOSE: The aim of this study was to investigate the **multidrug resistance** (MDR) pattern, MDR gene and P-glycoprotein (P-gp) expression, and P-gp function in drug-induced human T-lymphoblastoid leukemia MOLT-4 sublines. METHODS: The MDR sublines were developed by exposing the parental MOLT-4 cells to stepwise increasing concentrations of anticancer drugs daunorubicin (DNR), vinblastine (VBL) and doxorubicin (DOX). Degrees of resistance were assessed in terms of IC(50) values in an MTT assay and the P-gp function was evaluated in terms of rhodamine 123 (Rh123) accumulation and efflux. The percentage of cells undergoing apoptosis was determined by flow cytometry after staining with **annexin V-FITC** and propidium iodide. The levels of P-gp and MDR mRNA expression were estimated using the PE-conjugated anti-P-gp monoclonal antibody 17F9 and quantitative real-time reverse transcription-polymerase chain reaction. RESULTS: Three MOLT-4 sublines were established and revealed a 2- to 115-fold resistance to the anticancer reagents DNR, VBL and DOX as compared to the parental cell line. The highest MDR was expressed in MOLT-4/DNR cells, which was overcome by the P-gp modulator, cyclosporin A (CsA). The resistant sublines showed a decreased accumulation and an increased efflux of Rh123 in proportion to the degree of resistance, and these were completely reversed in the presence of 8 microM CsA. The decreased apoptotic response in these cell lines was clearly associated with the degree of drug resistance. P-gp antigen and MDR1 mRNA were highly expressed in both the MOLT-4/DNR and MOLT-4/DOX sublines. Less-resistant MOLT-4/VBL cells expressed lower levels of MDR1 mRNA and P-gp, even though the cell line was established by exposing the parental MOLT-4 cells to VBL for longer (5 months) than to the other two reagents (3 months). CONCLUSIONS: MOLT-4 cells were able to acquire a high level of drug resistance by culturing the cells in the presence of certain anticancer drugs, and acquisition of the resistance was relatively reagent-specific. The degrees of resistance to the anticancer drugs were well correlated with the expressions of MDR1 mRNA and functional P-gp, and were also associated with a decreased response to apoptosis.

ACCESSION NUMBER: 2002318051 MEDLINE  
DOCUMENT NUMBER: 21972412 PubMed ID: 11976833  
TITLE: Induction of **multidrug resistance** in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.  
AUTHOR: Liu Zhen-Li; Onda Kenji; Tanaka Sachiko; Toma Tsugutoshi; Hirano Toshihiko; Oka Kitaro  
CORPORATE SOURCE: Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Japan.  
SOURCE: CANCER CHEMOTHERAPY AND PHARMACOLOGY, (2002 May) 49 (5) 391-7.  
Journal code: 7806519. ISSN: 0344-5704.  
PUB. COUNTRY: Germany; Germany, Federal Republic of  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200206  
ENTRY DATE: Entered STN: 20020614  
Last Updated on STN: 20030105  
Entered Medline: 20020627

L3 ANSWER 10 OF 59 MEDLINE on STN

TI Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

AB It has been shown that the novel synthetic triterpenoid CDDO inhibits proliferation and induces differentiation and apoptosis in myeloid leukemia cells. In the current study the effects of the C-28 methyl ester of CDDO, CDDO-Me, were analyzed on cell growth and apoptosis of leukemic cell lines and primary acute myelogenous leukemia (AML). CDDO-Me decreased the viability of leukemic cell lines, including multidrug resistant (MDR)-1-overexpressing, p53(null) HL-60-Dox and of primary AML cells, and it was 3- to 5-fold more active than CDDO. CDDO-Me induced a loss of mitochondrial membrane potential, induction of caspase-3 cleavage, increase in annexin V binding and DNA fragmentation, suggesting the induction of apoptosis. CDDO-Me induced pro-apoptotic Bax protein that preceded caspase activation. Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less anti-apoptotic. CDDO-Me induced granulo-monocytic differentiation in HL-60 cells and monocytic differentiation in primary cells. Of significance, colony formation of AML progenitors was significantly inhibited in a dose-dependent fashion, whereas normal CD34(+) progenitor cells were less affected. Combinations with ATRA or the RXR-specific ligand LG100268 enhanced the effects of CDDO-Me on cell viability and terminal differentiation of myeloid leukemic cell lines. In conclusion, CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when given in submicromolar concentrations. Differential effects of CDDO-Me on leukemic and normal progenitor cells suggest that CDDO-Me has potential as a novel compound in the treatment of hematologic malignancies.

ACCESSION NUMBER: 2002055056 MEDLINE

DOCUMENT NUMBER: 21628800 PubMed ID: 11756188

TITLE: Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

AUTHOR: Konopleva Marina; Tsao Tzee; Ruvolo Peter; Stiouf Irina; Estrov Zeev; Leysath Clinton E; Zhao Shourong; Harris David; Chang Shirong; Jackson C Ellen; Munsell Mark; Suh Nanjoo; Gribble Gordon; Honda Tadashi; May W Stratford; Sporn Michael B; Andreeff Michael

CORPORATE SOURCE: Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

CONTRACT NUMBER: CA16672 (NCI)

CA44649 (NCI)

CA49639 (NCI)

CA55164 (NCI)

R01 CA 78814 (NCI)

SOURCE: BLOOD, (2002 Jan 1) 99 (1) 326-35.

Journal code: 7603509. ISSN: 0006-4971.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200201

ENTRY DATE: Entered STN: 20020125

Last Updated on STN: 20021214

Entered Medline: 20020128

L3 ANSWER 11 OF 59 MEDLINE on STN

TI Effects of butaclamol, clopenthixol, mepromazine and cannabinal stereoisomers on apoptosis induction.

AB The efflux pump of multidrug resistant **mdr** cells have different sensitivities to some stereoisomeric forms of CNS-active compounds. The ABC transporters of **mdr** cells were more sensitive to

(-)-butaclamol than to its stereoisomeric counterpart (8), which may function to alter the membrane structure. We suppose that the drug-accessible membrane structure possesses an important role in the induction (or prevention) of apoptosis. Therefore the apoptosis-inducing effect of three stereoisomeric pairs was studied on mouse lymphoma cells. In these experiments levo- and dextromepromazine had similar effects. The cis- and trans-clopenthixol were less effective in apoptosis induction than the 12H-benzo(a)-phenothiazine used as a positive control. The effect of stereoisomeric pairs on induced apoptosis was studied when the cells were exposed to the stereoisomers for 60 minutes before subjection apoptosis induction by benzo(a)phenothiazine, a well-known apoptosis inducer. Then the pretreated cells were exposed to 12H-benzo(a)-phenothiazine for 60 minutes. The samples were washed and incubated for 24 hours. The cells were stained with **annexin-V-FITC** and propidium iodine and investigated by flow cytometry. The **mdr** cells with increased membrane integrity may result in the preferential killing of multidrug resistant cancer cells in the presence of some stereoisomers.

ACCESSION NUMBER: 2001678077 MEDLINE  
DOCUMENT NUMBER: 21580870 PubMed ID: 11724344  
TITLE: Effects of butaclamol, clopenthixol, mepromazine and cannabinal stereoisomers on apoptosis induction.  
AUTHOR: Varga A; Sabat R; Mucsi I; Flores V C; Kaiser H E; Molnar J  
CORPORATE SOURCE: Department of Molecular Parasitology, Humboldt University, Berlin, Germany.  
SOURCE: ANTICANCER RESEARCH, (2001 Jul-Aug) 21 (4A) 2709-12.  
Journal code: 8102988. ISSN: 0250-7005.  
PUB. COUNTRY: Greece  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200112  
ENTRY DATE: Entered STN: 20011129  
Last Updated on STN: 20020123  
Entered Medline: 20011207

L3 ANSWER 12 OF 59 MEDLINE on STN

TI Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro.

AB The cytotoxic activity of the non-steroidal anti-inflammatory agent ibuprofen to human promyelocytic leukemia cell line HL-60, its multidrug-resistant subline HL-60/VCR (**MDR**-1 gene coded P-glycoprotein), as well as myeloma U266 and B-lymphoblastoid ARH-77 cell lines was demonstrated with the aid of flow cytometric analysis. Ibuprofen inhibited proliferation and induced apoptosis (detected as sub-G0 nuclei, fluorescein diacetate staining, **Annexin-V** binding cells and agarose electrophoretic detection of nucleosomal DNA fragmentation) in promyelocytic cells and, to a lesser extent, in U266 and ARH-77 cells.

ACCESSION NUMBER: 2001535506 MEDLINE  
DOCUMENT NUMBER: 21466982 PubMed ID: 11583291  
TITLE: Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro.  
AUTHOR: Jakubikova J; Duraj T; Takacsova X; Hunakova L; Chorvath B; Sedlak J  
CORPORATE SOURCE: Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovak Republic.. exonjana@savba.sk  
SOURCE: NEOPLASMA, (2001) 48 (3) 208-13.  
Journal code: 0377266. ISSN: 0028-2685.  
PUB. COUNTRY: Slovakia  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals



ENTRY MONTH: 200110  
ENTRY DATE: Entered STN: 20011004  
Last Updated on STN: 20011022  
Entered Medline: 20011018

L3 ANSWER 13 OF 59 MEDLINE on STN

TI **Multidrug-resistance** phenotype and clinical responses to gemtuzumab ozogamicin.

AB Expression of **multidrug resistance (MDR)** features by acute myeloid leukemia (AML) cells predicts a poor response to many treatments. The **MDR** phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML. Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD33 antibody linked to calicheamicin, is effective monotherapy for CD33(+) relapsed AML. However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined. In this study, blast cell samples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for Pgp surface expression and Pgp function using a dye efflux assay. In most cases, surface expression of Pgp correlated with Pgp function, as indicated by elevated dye efflux that was inhibited by CSA. Among samples from patients who either failed to clear marrow blasts or failed to achieve remission, 72% or 52%, respectively, exhibited CSA-sensitive dye efflux compared with 29% (P = .003) or 24% (P < .001) among samples from responders. In vitro gemtuzumab ozogamicin--induced apoptosis was also evaluated using an **annexin V**--based assay. Low levels of drug-induced apoptosis were associated with CSA-sensitive dye efflux, whereas higher levels correlated strongly with achievement of remission and marrow blast clearance. In vitro drug-induced apoptosis could be increased by CSA in 14 (29%) of 49 samples exhibiting low apoptosis in the absence of CSA. Together, these findings indicate that Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials combining gemtuzumab ozogamicin with **MDR** reversal agents are warranted. (Blood. 2001;98:988-994)

ACCESSION NUMBER: 2001446293 MEDLINE

DOCUMENT NUMBER: 21384755 PubMed ID: 11493443

TITLE: **Multidrug-resistance** phenotype and clinical responses to gemtuzumab ozogamicin.

AUTHOR: Linenberger M L; Hong T; Flowers D; Sievers E L; Gooley T A; Bennett J M; Berger M S; Leopold L H; Appelbaum F R; Bernstein I D

CORPORATE SOURCE: Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.. linen@u.washington.edu

SOURCE: BLOOD, (2001 Aug 15) 98 (4) 988-94.  
Journal code: 7603509. ISSN: 0006-4971.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200109

ENTRY DATE: Entered STN: 20010813  
Last Updated on STN: 20020716  
Entered Medline: 20010920

L3 ANSWER 14 OF 59 MEDLINE on STN

TI Potent induction of apoptosis by beta-lapachone in human multiple myeloma cell lines and patient cells.

AB BACKGROUND: Human multiple myeloma (MM) remains an incurable hematological malignancy. We have reported that beta-lapachone, a pure compound derived from a plant, can induce cell death in a variety of human carcinoma cells, including ovary, colon, lung, prostate, pancreas, and breast, suggesting a wide spectrum of anticancer activity. MATERIALS AND METHODS: We first studied antisurvival effects of beta-lapachone in human MM cells by colony

formation assay. To determine whether the differential inhibition of colony formation occurs through antiproliferative activity, we performed MTT assays. The cytotoxicity of beta-lapachone on human peripheral blood mononuclear cells was also measured by MTT assay. To determine whether the cell death induced by beta-lapachone occurs through necrosis or apoptosis, we used the propidium iodide staining procedure to determine the sub-G1 fraction, **Annexin-V** staining for externalization of phosphatidylserine, and fragmentation of cellular genomic DNA subjected to gel electrophoresis. To investigate the mechanism of anti-MM activity, we examined Bcl-2 expression, cytochrome C release, and poly (ADP ribose) polymerase cleavage by Western blot assay. RESULTS: We found that beta-lapachone (less than 4 microM) inhibits cell survival and proliferation by triggering cell death with characteristics of apoptosis in ARH-77, HS Sultan, and MM.1S cell lines, in freshly derived patient MM cells (MM.As), MM cell lines resistant to dexamethasone (MM.1R), doxorubicin (DOX.40), mitoxantrone (MR.20), and mephalan (LR5). Importantly, after treatment with beta-lapachone, we observed no apoptosis in peripheral blood mononuclear cells in either quiescent or proliferative states, freshly isolated from healthy donors. In beta-lapachone treated ARH-77, cytochrome C was released from mitochondria to cytosol, and poly (ADP ribose) polymerase was cleaved, signature events of apoptosis. Finally, the apoptosis induced by beta-lapachone in MM cells was not blocked by either interleukin-6 or Bcl-2, which confer **multidrug resistance** in MM. CONCLUSIONS: Our results suggest potential therapeutic application of beta-lapachone against MM, particularly to overcome drug resistance in relapsed patients.

ACCESSION NUMBER: 2001441865 MEDLINE  
DOCUMENT NUMBER: 21366316 PubMed ID: 11474117  
TITLE: Potent induction of apoptosis by beta-lapachone in human multiple myeloma cell lines and patient cells.  
AUTHOR: Li Y; Li C J; Yu D; Pardee A B  
CORPORATE SOURCE: Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA..  
Youzhi\_Li@dfci.harvard.edu  
CONTRACT NUMBER: R01 CA61253 (NCI)  
SOURCE: MOLECULAR MEDICINE, (2000 Dec) 6 (12) 1008-15.  
Journal code: 9501023. ISSN: 1076-1551.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200108  
ENTRY DATE: Entered STN: 20010813  
Last Updated on STN: 20010820  
Entered Medline: 20010816

L3 ANSWER 15 OF 59 MEDLINE on STN

TI Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.

AB A2780 sensitive and A2780/AD doxorubicin (DOX) resistant human ovarian carcinoma cells were exposed to different concentrations (0.25, 0.5, 1, 5 and 10xIC(50)) of free and HPMA copolymer-bound DOX for 12, 24, 36, 48, 60 and 72 h. Apoptosis and necrosis were evaluated using the FITC-conjugated **annexin V** and propidium iodide staining. The data obtained showed that the induction of apoptosis and necrosis by both free DOX and HPMA copolymer-bound DOX were time- and concentration-dependent. The data also showed significant differences between the drugs. It was found that: (i) under the action of HPMA copolymer-bound doxorubicin the alterations in the plasma membrane permeability preceded disturbances in cellular metabolism; (ii) HPMA copolymer-bound doxorubicin kills the cells mainly by necrosis; (iii) HPMA copolymer-bound doxorubicin is a more effective anticancer drug than free doxorubicin.

ACCESSION NUMBER: 2001052226 MEDLINE

DOCUMENT NUMBER: 20473531 PubMed ID: 11018556  
TITLE: Time- and concentration-dependent apoptosis and necrosis induced by free and HPMa copolymer-bound doxorubicin in human ovarian carcinoma cells.  
AUTHOR: Demoy M; Minko T; Kopeckova P; Kopecek J  
CORPORATE SOURCE: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.  
CONTRACT NUMBER: CA 51578 (NCI)  
SOURCE: JOURNAL OF CONTROLLED RELEASE, (2000 Oct 3) 69 (1) 185-96. Journal code: 8607908. ISSN: 0168-3659.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200012  
ENTRY DATE: Entered STN: 20010322  
Last Updated on STN: 20010322  
Entered Medline: 20001213